Is the FDA Contributing to the Homelessness Crisis?

In a recent op-ed for The Hill, Dr. Jeffrey Singer, and co-author Josh Bloom, PhD, Director of Chemical and Pharmaceutical Research at the American Council on Science and Health, discuss the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program as a barrier contributing to the homelessness crisis among individuals with severe mental illnesses like schizophrenia. Singer notes that two-thirds of homeless individuals suffer from mental health issues, many requiring effective treatments such as clozapine. However, stringent REMS requirements hinder access to this essential medication, exacerbating challenges for vulnerable patients. Singer argues that while drug safety is important, these regulations disproportionately impact those in need, calling for the elimination of the REMS program to enhance access to life-saving treatments.

As an expert on this subject, Dr. Singer welcomes inquiries for interviews regarding future work on this topic or topics surrounding FDA reform.